Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 14 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

2 trials in Phase 3/4

Results Transparency

1 of 11 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

8(66.7%)

Phase 3

2(16.7%)

Phase 2

2(16.7%)

12Total

Phase 1(8)

Phase 3(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT06083623Phase 2Completed

A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

Role: lead

NCT06710925Phase 3Completed

A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants

Role: lead

NCT07347938Not Yet Recruiting

A Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

Role: lead

NCT07107932Recruiting

A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

Role: lead

NCT05625477Phase 2Completed

Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers

Role: lead

NCT06607380Phase 1Completed

A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine

Role: lead

NCT06068608Phase 1Unknown

A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy

Role: lead

NCT05630573Phase 1Completed

A Study of TNM001 in Chinese Healthy Preterm and Term Infants

Role: lead

NCT05664750Phase 3Completed

Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus

Role: lead

NCT05842798Phase 1Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults

Role: lead

NCT04629131Phase 1Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy Adults

Role: lead

NCT02709616Phase 1Completed

Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)

Role: collaborator

NCT02808364Phase 1Completed

Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)